

UnitedHealthcare Community Plan Medical Policy Update Bulletin Quick View: October 2025



A list of recently approved, revised, and/or retired Medical Policies and/or Medical Benefit Drug Policies is provided below for your reference. **For a comprehensive summary of the latest updates, refer to the [Medical Policy Update Bulletin: October 2025](#).**

Take Note

Annual ICD-10 and Quarterly HCPCS Code Updates

Beginning **Oct. 1, 2025**, all applicable Medical Benefit Drug Policies will be updated to reflect the annual ICD-10 and quarterly HCPCS code additions, revisions, and deletions. Refer to the following sources for information on the code updates:

- Centers for Medicare & Medicaid Services: Healthcare Common Procedure Coding System (HCPCS) Quarterly Update
- Centers for Medicare & Medicaid Services: International Classification of Diseases, Tenth Revision (ICD-10) Codes

Refer to the Medical Policy Update Bulletin: October 2025 for a list of impacted policies and corresponding details.

Medical Policy Updates

Policy Title	Status	Effective Date
Brow Ptosis and Eyelid Repair	Updated	Oct. 1, 2025
Cognitive Rehabilitation and Coma Stimulation	Revised	Dec. 1, 2025
Electroretinography	Retired	Oct. 1, 2025
Glaucoma Surgical Treatments	Revised	Dec. 1, 2025
Hospital Services: Observation and Inpatient	Revised	Dec. 1, 2025
Remote Physiologic Monitoring (RPM)	New	Jan. 1, 2026
Respiratory Pathogen Nucleic Acid Detection Testing	New	Jan. 1, 2026

Medical Benefit Drug Policy Updates

Policy Title	Status	Effective Date
Buprenorphine (Brixadi® & Sublocade®)	Revised	Nov. 1, 2025
Edaravone	Updated	Oct. 1, 2025
Encelto™ (Revakinagene Taroretcel-Lwey)	Updated	Oct. 1, 2025
Factor Mimetics and Rebalancing Agents for Hemophilia	Revised	Nov. 1, 2025
FcRn Blockers (Rystiggo®, Vyvgart®, & Vyvgart Hytrulo®)	Revised	Nov. 1, 2025
Hereditary Angioedema (HAE), Treatment and Prophylaxis	Updated	Oct. 1, 2025
Ilaris® (Canakinumab)	Updated	Oct. 1, 2025
Krystexxa® (Pegloticase)	Updated	Oct. 1, 2025
Leqvio® (Inclisiran)	Updated	Oct. 1, 2025
Long-Acting Injectable Antiretroviral Agents for HIV	Revised	Nov. 1, 2025

Policy Title	Status	Effective Date
Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease	Revised	Nov. 1, 2025
Nplate® (Romiplostim)	Updated	Oct. 1, 2025
Ocrevus® (Ocrelizumab) and Ocrevus Zunovo™ (Ocrelizumab and Hyaluronidase-Ocsq)	Updated	Oct. 1, 2025
Skyrizi® (Risankizumab-Rzaa)	Updated	Oct. 1, 2025
Synagis® (Palivizumab)	Revised	Nov. 1, 2025

General Information

The inclusion of a health service (e.g., test, drug, device, or procedure) in this bulletin indicates only that UnitedHealthcare is adopting a new policy and/or updated, revised, replaced, or retired an existing policy; it does not imply that UnitedHealthcare provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

Note: The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Medical Policy Update Bulletin was developed to share important information regarding changes to our Community Plan Medical Policies and Medical Benefit Drug Policies. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare follows such applicable federal and/or state law.

Policy Update Classifications

New

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device, or procedure)

Updated

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

Revised

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

Replaced

An existing policy has been replaced with a new or different policy

Retired

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of UnitedHealthcare Community Plan Medical Policies and Medical Benefit Drug Policies is available at [UHCprovider.com](https://www.uhcprovider.com) > Policies and Protocols > Community Plan Policies > Medical & Drug Policies.